Lawrence J. Hineline Sells 3,192 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) CFO Lawrence J. Hineline sold 3,192 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $15.67, for a total transaction of $50,018.64. Following the completion of the sale, the chief financial officer now owns 68,686 shares in the company, valued at $1,076,309.62. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded up $0.13 during mid-day trading on Friday, hitting $17.47. 989,961 shares of the company’s stock were exchanged, compared to its average volume of 443,629. Intra-Cellular Therapies Inc. has a one year low of $7.85 and a one year high of $22.67. The company has a market cap of $953.47, a P/E ratio of -7.98 and a beta of 0.72.
Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, hitting analysts’ consensus estimates of ($0.53). Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million. During the same period in the previous year, the firm earned ($0.70) EPS. Intra-Cellular Therapies’s revenue was up 675.0% on a year-over-year basis. sell-side analysts predict that Intra-Cellular Therapies Inc. will post -2.13 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in ITCI. Perceptive Advisors LLC bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth about $14,667,000. Wasatch Advisors Inc. raised its position in shares of Intra-Cellular Therapies by 65.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after buying an additional 654,400 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth about $8,663,000. Dimensional Fund Advisors LP raised its position in shares of Intra-Cellular Therapies by 419.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after buying an additional 522,565 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Intra-Cellular Therapies by 336.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after buying an additional 447,586 shares in the last quarter. Institutional investors own 74.47% of the company’s stock.
ITCI has been the topic of several recent research reports. ValuEngine downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 5th. BidaskClub downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. SunTrust Banks reiterated a “hold” rating and issued a $22.00 price objective (up from $16.00) on shares of Intra-Cellular Therapies in a research report on Friday, September 8th. Finally, Canaccord Genuity initiated coverage on shares of Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $25.56.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with Analyst Ratings Network's FREE daily email newsletter.